The tweet was deleted by the author.
But we saved everything 🙂.
Pathway Labs has secured its first institutional investment, led by Breyer Capital, to advance its EchoNext system, an artificial intelligence platform that detects structural heart disease using standard ECG data. Pathway Labs also achieved a milestone by receiving the first FDA clearance for a multi-condition AI system in U.S. cardiology. Cardiovascular disease remains a leading health issue globally, underscoring the significance of innovations such as EchoNext.
View post on X Loading...